PEMBROLIZUMAB AND BEVACIZUMAB IN PLATINUM RESISTANT EPITHELIAL OVARIAN CANCER PATIENTS

被引：1
|
作者：
Michels, Judith [1 ]
Frenel, Jean-Sebastien [2 ]
Genestie, Catherine [3 ]
Ghiringhelli, Francois [4 ]
Brard, Caroline [3 ]
You, Benoit [5 ]
Floquet, Anne [6 ]
Eberst, Lauriane [7 ]
Bahleda, Rastilav [1 ]
Balleyguier, Corinne [1 ]
Paci, Angelo [1 ]
Ciccolini, Joseph [8 ]
Colomba, Emeline [1 ]
Pommeret, Fanny [1 ]
Massard, Christophe
Pautier, Patricia [1 ]
Marabelle, Aurelien [1 ]
Leary, Alexandra [1 ]
机构：
[1] Gustave Roussy Inst, Paris, France
[2] Inst Cancerol IOuest, St Herblain, France
[3] Gustave Roussy, Villejuif, France
[4] Ctr Georges Francois Leclerc, Dijon, France
[5] Inst Cancerol Hosp Ci, Lyon, France
[6] Inst Bergonie, Bordeaux, France
[7] Inst Cancerol Strasbourg, Strasbourg, France
[8] La Timone Univ Hosp, Marseille, France
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.355
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
355
引用
收藏
页码：A382 / A382
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
    Michels, Judith
    Ghiringhelli, Francois
    Frenel, Jean-Sebastien
    Brard, Caroline
    You, Benoit
    Floquet, Anne
    Eberst, Lauriane
    Bahleda, Rastilav
    Genestie, Catherine
    Balleyguier, Corinne
    Broutin, Sophie
    Pautier, Patricia
    Colomba, Emeline
    Pommeret, Fanny
    Massard, Christophe
    Marabelle, Aurelien
    Leary, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Bevacizumab exposure and tumor response in patients with platinum resistant epithelial ovarian cancer.
    Michels, Judith
    Hamimed, Mourad
    Menu, Yves
    Balleyguier, Corinne
    Ghiringhelli, Francois
    Frenel, Jean-Sebastien
    Genestie, Catherine
    You, Benoit
    Floquet, Anne
    Eberst, Lauriane
    Paci, Angelo
    Bahleda, Rastilav
    Pautier, Patricia
    Colomba, Emeline
    Pommeret, Fanny
    Leary, Alexandra
    Marabelle, Aurelien
    Bardet, Aurelie
    Brard, Caroline
    Ciccolini, Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] EFFECTIVENESS OF BEVACIZUMAB IN PLATINUM-RESISTANT RECURRENT EPITHELIAL OVARIAN CANCER
    Pinto, R.
    Monteiro, S.
    Lima, B.
    Lopes, A. R.
    Abreu, M.
    Ferreira, M.
    Sousa, S.
    Redondo, P.
    Pereira, D.
    Savva-Bordalo, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A271 - A271
  • [4] Bevacizumab in patients with advanced platinum-resistant ovarian cancer.
    Cannistra, S. A.
    Matulonis, U.
    Penson, R.
    Wenham, R.
    Armstrong, D.
    Burger, R. A.
    Mackey, H.
    Douglas, J.
    Hambleton, J.
    McGuire, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 257S - 257S
  • [5] BEVACIZUMAB IN THE TREATMENT FOR PLATINUM-RESISTANT EPITHELIAL OVARIAN CARCINOMA
    Cuellar Angeles, Flores
    Yanez Elena, Sanchez
    Contreras Josefina, Gonzalez
    ATENCION FARMACEUTICA, 2011, 13 (01): : 8 - +
  • [6] Immune characterization in platinum resistant ovarian cancer patients treated with pembrolizumab and guadecitabine
    Xie, Ping
    Chen, Siqi
    Cowan, Mathew
    Huang, Hao
    Cardenas, Horacio
    Kocherginsky, Masha
    Matei, Daniela
    Zhang, Bin
    JOURNAL OF IMMUNOLOGY, 2022, 208 (01):
  • [7] Doxorubicin hydrochloride and bevacizumab for the patients with platinum-taxane resistant ovarian cancer
    Ota, T.
    Sugimori, Y.
    Fujino, K.
    Ujihira, T.
    Kusunoki, S.
    Kimura, M.
    Terao, Y.
    Ogishima, D.
    Takeda, S.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (06) : 889 - 893
  • [8] Feasibility of bevacizumab combined with gemcitabine in treatment of platinum-resistant epithelial ovarian cancer.
    Kogiku, Ai
    Nagao, Shoji
    Suzuki, Kazuhiro
    Yamamoto, Kasumi
    Senda, Tokihiro
    Kitai, Miho
    Shiozaki, Takaya
    Matsuoka, Kazuko
    Sudo, Tamotsu
    Yamaguchi, Satoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer
    Andrikopoulou, Angeliki
    Liontos, Michalis
    Skafida, Efthymia
    Koutsoukos, Konstantinos
    Apostolidou, Kleoniki
    Kaparelou, Maria
    Rouvalis, Angeliki
    Bletsa, Garyfallia
    Dimopoulos, Meletios-Athanasios
    Zagouri, Flora
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (04) : 571 - 576
  • [10] Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer
    Seol, Aeran
    Kim, Se ik
    Yoon, Hee yeun
    Lee, Maria
    Kim, Hee seung
    Chung, Hyun hoon
    Park, Noh hyun
    Song, Yong sang
    IN VIVO, 2024, 38 (03): : 1338 - 1350
12345